36.6 F
New York
Wednesday, January 27, 2021

Gilead Sciences [NASDAQ: GILD] To Acquire Tizona Therapeutics For $300 Million

Must read

Nova Lifestyle [NASDAQ: NVFY] Announces The Inauguration Of HealthLine Membership In The Malaysian Market

Nova lifestyle revealed that the company is planning to inaugurate a HealthLine platform based on membership in Malaysia. The company recently launched an...

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Gilead Sciences, Inc. [NASDAQ: GILD] disclosed today it has acquired 49.9% equity interest in Tizona Therapeutics, Inc. for $300 million. Tizona Therapeutics, Inc. is a privately held firm engaged in the making of first-in-class immunotherapies.

Gilead Sciences also has the option to acquire the remaining shares of Tizona in an additional $1.25 billion, including an option exercise fee and future milestone payments. Gilead Sciences has the opportunity to buy the remainder of Tizona before or following the readout of Phase 1b study of Tizona’s investigational antibody, TTX-080.

Investigational antibody TTX-080 discovered by Tizona is a first-in-class drug that targets HLA-G. US Food and Drug Authority has given the all-clear for the application of TTX-080. Tizona is planning to start the phase 1 clinical trial to check TTX-080 both as monotherapy and in combination with other agents in patients with advanced cancers.

Shares of Gilead Sciences have exhibited a change of 0.67% during the trading of Tuesday. It has a day low and high range of $77.20-$77.89, respectively. GILD has a closing price of $77.56 and has opened at $77.46. In the past 52-weeks of trading, this company’s stocks have changed between the low of $60.89 and a high of $85.97.

If we turn our focus on profitability, it has a return on assets of 8.10%, its return on equity is 22.60% and return on investment is 9.50%. This company’s gross margin is 79.40%, the profit margin is 21.80% and an operating margin is 19.60%.

More articles

Latest article

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...